Bortezomib paradigm shift in myeloma

Research output: Contribution to journalComment/debatepeer-review

Abstract

Bortezomib's unprecedented antitumor activity in myeloma has long been attributed to NF-κB inhibition. A new study from the group that put the drug on the map directly challenges this assumption.

Original languageEnglish (US)
Pages (from-to)931-932
Number of pages2
JournalBlood
Volume114
Issue number5
DOIs
StatePublished - 2009
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Bortezomib paradigm shift in myeloma'. Together they form a unique fingerprint.

Cite this